In patients with chronic migraine, adding atogepant to onabotulinumtoxinA significantly reduces the burden of migraine, achieving a ≥ 50% response with a favourable safety profile.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/onabotulinumtoxina-plus-atogepant-shows-promise-chronic-2025a1000yac?src=rss
Author :
Publish date : 2025-12-10 12:00:00
Copyright for syndicated content belongs to the linked Source.